Methotrexate Pfizer

Methotrexate, the active ingredient in Methotrexate Pfizer, is an antimetabolite presented as an oral formulation for oral administration. It functions as a disease-modifying antirheumatic drug and chemotherapeutic agent, indicated for rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, osteosarcoma, and gestational trophoblastic disease, providing therapeutic benefit in adults and selected pediatric cases.

GNH USA supplies Methotrexate Pfizer as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across global markets.

Methotrexate is used in several disease categories, primarily targeting inflammatory and proliferative disorders. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin lesion severity and plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation to achieve remission. - Osteosarcoma: inhibits tumor growth as part of multimodal therapy. - Gestational trophoblastic disease: promotes resolution of trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: general tiredness. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Severe liver toxicity: risk of hepatic fibrosis or cirrhosis. - Pulmonary toxicity: interstitial pneumonitis. - Bone marrow suppression: pancytopenia. - Severe cutaneous reactions: Stevens‑Johnson syndrome.

When prescribing methotrexate, several precautions should be observed to minimize risk. - Pregnancy contraindication: avoid use in pregnancy (Category X) due to teratogenicity. - Breastfeeding restriction: do not breastfeed while on therapy. - Baseline labs: obtain liver function tests, renal function and complete blood count before initiation. - Monitoring: regularly assess hepatic enzymes, renal function and blood counts during treatment. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Methotrexate interacts with several medicines; awareness of major and moderate interactions helps guide safe use.

Major Interactions (Avoid): - NSAIDs: increase renal toxicity risk. - Proton pump inhibitors: may raise methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: enhances myelosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone marrow suppression. - High‑dose penicillins: can reduce renal clearance. - Phenytoin: may alter methotrexate metabolism.